Meeting
2019 ASCO Quality Care Symposium
A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk.
Authors
Gary H. Lyman
Fred Hutchinson Cancer Research Center, Seattle, WA
Gary H. Lyman, Dylan Mezzio, Edward C. Li, Kim Campbell, Sanjeev Balu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cost, Value, and Policy; Health Equity and Disparities
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 37, 2019 (suppl 27; abstr 107)
DOI
10.1200/JCO.2019.37.27_suppl.107
Abstract #
107
Poster Bd #
H6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Evaluation of outcomes between rituximab-abbs and reference product rituximab in adult patients with newly diagnosed diffuse large B-cell lymphoma in a non-inferiority study.
First Author: Vivian Nguyen
Poster
2023 ASCO Annual Meeting
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.
First Author: Lorenzo Falchi
Poster
2022 ASCO Annual Meeting
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.
First Author: Lorenzo Falchi
Poster
2020 ASCO Quality Care Symposium
Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.
First Author: Edward C. Li